Condition
    Effectiveness 3/5

    N-Acetyl Cysteine (NAC) for Chronic Bronchitis

    N-acetylcysteine (NAC) is the best-evidenced supplement in chronic bronchitis: as a mucolytic it breaks disulfide bonds in mucus, and as a glutathione precursor it counters the oxidative stress driving airway inflammation. Meta-analyses of randomized trials show NAC at 1,200 mg/day reduces COPD/chronic-bronchitis exacerbation frequency by roughly 20–30%, with the clearest benefit in patients not on inhaled corticosteroids. It is an adjunct with real data — but it rides on top of the intervention that actually changes the disease: quitting smoking.

    Overview

    N-acetylcysteine is one of the older mucolytics, and in chronic bronchitis its value is exacerbation prevention rather than day-to-day symptom relief. Cochrane review data show fewer exacerbations and fewer days of illness with regular use, with a number needed to treat that is modest but real. Effects on lung function are essentially absent. NAC does not change FEV1 decline in the trials that measured it.
    Dose appears to matter. The 2005 BRONCUS trial used 600 mg once daily and found no reduction in exacerbations, while the 2014 PANTHEON trial used 600 mg twice daily and did show a reduction. The Cochrane analysis supports the higher-dose picture, particularly in patients not taking inhaled corticosteroids. That inconsistency is why the verdict is likely rather than strong.

    How It Works

    NAC carries a free sulfhydryl group that cleaves the disulphide bonds cross-linking mucin polymers. Breaking those bridges lowers sputum viscosity and makes secretions easier to clear, which is the classical mucolytic action. Easier clearance reduces the mucus plugging and bacterial colonisation that drive the exacerbation cycle in chronic bronchitis.
    NAC is also a cysteine donor for glutathione synthesis, and airway glutathione is depleted in smokers and in COPD. Restoring it improves the local antioxidant buffer against cigarette smoke and inflammatory oxidants. At higher plasma concentrations NAC additionally suppresses NF-kappa-B signalling and pro-inflammatory cytokine release, which is a plausible explanation for why 1200 mg per day outperformed 600 mg per day in the trials.

    Dosing & Protocol

    The regimen with positive exacerbation data is 600 mg twice daily, giving 1200 mg per day, taken long term. PANTHEON ran for one year; the Cochrane analyses cover trials of several months upward. Effervescent and standard oral forms were both used. Taking it with food reduces the nausea that some people experience at the higher dose.

    This is an add-on

    NAC supplements inhaled therapy, smoking cessation and pulmonary rehabilitation. It does not replace any of them, and it does not improve lung function.

    Evidence

    Three linked sources define this pairing: the 2019 Cochrane review of mucolytics versus placebo in chronic bronchitis and COPD, the 2014 PANTHEON randomised trial in Lancet Respiratory Medicine using 600 mg twice daily, and the 2005 BRONCUS trial in The Lancet using 600 mg once daily. The two randomised trials disagree, and dose is the most plausible explanation. Cochrane concludes mucolytics produce a small reduction in exacerbations and disability days.

    Studies linked to this pairing.

    Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease

    Score: 9/10
    2019
    meta_analysis

    Poole P, Sathananthan K, Fortescue R

    Mucolytics produced a small reduction in the likelihood of exacerbations and in days of disability in chronic bronchitis or COPD.

    View source

    Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial

    Score: 9/10
    2005
    rct
    n=523

    Decramer M, Rutten-van Molken M, Dekhuijzen PN +9 more

    N-acetylcysteine did not slow the decline in FEV1 and did not reduce exacerbation rates overall.

    View source

    Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial

    Score: 8/10
    2014
    rct
    n=1006

    Zheng JP, Wen FQ, Bai CX +11 more

    N-acetylcysteine 1200 mg/day significantly reduced the annual exacerbation rate compared with placebo.

    View source

    Safety

    Oral NAC is well tolerated at 1200 mg per day. Nausea, heartburn and diarrhoea are the most common complaints and are reduced by taking doses with food. A sulphurous smell is characteristic and harmless. Bronchospasm has been reported, mainly with nebulised NAC in people with asthma, and is uncommon with oral use.

    Bleeding and asthma

    NAC has mild antiplatelet activity, so stop it before planned surgery and use caution with anticoagulants. People with asthma should watch for wheeze when starting.

    Interactions & Conflicts

    The interaction that matters most clinically is with nitroglycerin, where NAC potentiates vasodilation and can cause marked hypotension and headache. Additive bleeding risk with anticoagulants and antiplatelet drugs is the second consideration. NAC can also chelate metal ions, so iron, zinc and copper supplements should be separated from the dose by a couple of hours. Older advice about deactivating antibiotics applies to mixing them in solution, not to separated oral dosing.
    Interacts withSeverityMechanismAction
    high
    		——
    moderate
    		——
    moderate
    		——
    low
    		——
    moderate
    		——

    References

    Frequently Asked Questions

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.